KRSNAA
Krsnaa Diagnostics
Each stock's 10,000-path forecast, rendered as light.
Krsnaa Diagnostics (KRSNAA) Stock Analysis & Case Study
Is KRSNAA a good buy? The data-driven verdict.
Krsnaa Diagnostics (KRSNAA) trades at ₹535,on the numbers it tread carefully, a Downstox Snapshot Score of 43/100.
On the numbers, Krsnaa Diagnostics (KRSNAA) tread carefully, a Downstox Snapshot Score of 43/100, weighing fairly valued at 17.1× earnings, ROE of 10.9%, a 33% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
KRSNAA fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is KRSNAA overvalued? KRSNAA P/E vs its sector
KRSNAA's P/E of 17.1× sits above the sector peer median of 15.9×, so on earnings it screens in line with peers, while its 0.51% dividend yield is below the peer median of 1.65%.
KRSNAA share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of KRSNAA history (-9%/yr drift, 36%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| KRSNAA 2027 | ₹288 | ₹458 | ₹719 | -14% |
| KRSNAA 2028 | ₹208 | ₹395 | ₹754 | -26% |
| KRSNAA 2029 | ₹156 | ₹341 | ₹749 | -36% |
| KRSNAA 2030 | ₹118 | ₹293 | ₹719 | -45% |
| KRSNAA 2031 | ₹91 | ₹249 | ₹691 | -53% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability KRSNAA goes up, or doubles?
The bull case for KRSNAA
- A 17.1× P/E sits in the fair-value band, neither cheap nor stretched.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹749.
The bear case & risks
- Return on equity is a soft 10.9%, capital efficiency trails higher-quality peers.
- The probability model is cautious 12 months out, only a 33% chance of finishing above today's price.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹156.
KRSNAA volatility & expected range, how bumpy is the ride?
Over the last 2.0 years KRSNAA compounded at -9%/year with annualized volatility of 36%. That volatility implies a 1-year 80% range of ₹288–₹719, the honest backbone behind any single price target.
KRSNAA price forecast, the full 60-month probability fan
KRSNAA price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds KRSNAA hits common targets within the simulated horizon?
Full multi-horizon detail on the KRSNAA price target & forecast page.
KRSNAA Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. KRSNAA scores 4/9,mixed financial health.
KRSNAA MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy KRSNAA with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.0% | 2.9× |
| ZerodhaCHEAPEST | 30.9% | 3.2× |
| Dhan | 40.0% | 2.5× |
Compare every broker on the KRSNAA MTF page.
KRSNAA vs peers,sector comparison
About Krsnaa Diagnostics: sector, index & market-cap context
Krsnaa Diagnostics (KRSNAA) is a small-cap NSE-listed company, and a constituent of the Nifty 500 index group, with a market capitalisation of ₹1,733 Cr. See more Nifty 500 stocks.
How the KRSNAA Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Krsnaa Diagnostics's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
KRSNAA analysis, FAQs
Is Krsnaa Diagnostics (KRSNAA) a good buy?
On the numbers, Krsnaa Diagnostics (KRSNAA) tread carefully, a Downstox Snapshot Score of 43/100, weighing fairly valued at 17.1× earnings, ROE of 10.9%, a 33% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is KRSNAA overvalued or undervalued?
KRSNAA trades at 17.1× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the KRSNAA share price target for 2031?
KRSNAA's probability-weighted 2031 median target is ₹249, with an 80% range of ₹91–₹691 (10,000-path Monte-Carlo).
What is the probability KRSNAA doubles in 5 years?
The modelled probability of KRSNAA reaching ₹1,063 (2×) within 5 years is 3%.
What is the bull case for KRSNAA?
A 17.1× P/E sits in the fair-value band, neither cheap nor stretched.
What are the risks in KRSNAA?
Return on equity is a soft 10.9%, capital efficiency trails higher-quality peers. The probability model is cautious 12 months out, only a 33% chance of finishing above today's price.